News Amgen/UCB's osteoporosis drug hit by cardio risk Competitor to Amgen's Epogen also moves closer to market
News Sandoz buys into Durect's long-acting painkiller Sandoz has signed a potential $293 million agreement to develop and market Durect’s Posimir, an extended-release, locally-acting, non-opioid painkiller in the US.
News Report links Sanofi epilepsy drug with thousands of birth de... Depakine and generics linked with defects including spina bifida.
News Mylan recalls pricey US EpiPens, but cheaper version unaffec... More trouble for embattled Mylan.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.